Long-Term Remission With Low-Dose Rituximab in Myasthenia Gravis: A Retrospective Study.

Juan Ignacio CastiglioneAlberto D RiveroFabio BarrosoPatricio BrandAndrea LautreAlejandro A Kohler

Published in: Journal of clinical neuromuscular disease (2022)

Low-dose RTX infusions were sufficient to achieve undetectable CD19/20 cell counts and sustained clinical remission. In low and middle-income countries, the impact of low-dose RTX therapy represents a paradigm shift in decision-making for long-term treatment.

Keyphrases

low dose
myasthenia gravis
high dose
decision making
disease activity
cell therapy
ulcerative colitis
diffuse large b cell lymphoma
rheumatoid arthritis
stem cells
systemic lupus erythematosus
mesenchymal stem cells
hodgkin lymphoma
replacement therapy